FDA Approves Glofitamab-gxbm to Treat Adults With Relapsed/Refractory DLBCL

Glofitamab is the first bispecific antibody with a fixed-duration treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Related Keywords

Sweden ,United States ,Copenhagen ,Køavn ,Denmark ,Swedish ,American ,Krish Patel ,Martin Hutchings ,Genentech Columvi ,Levi Garraway ,Lymphoma Program ,Global Product Development ,Leukemia Lymphoma Society ,Swedish Cancer Institute In Seattle ,American Society Of Hematology ,Genentech ,Department Of Hematology ,Copenhagen University Hospital ,Swedish Cancer Institute ,American Society ,Accessed June ,Dlbcl ,Glofitamab ,Fda Approval ,